The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Blinded-assessment of a solution to evaluate olaparib maintenance treatment efficacy in patients with ovarian cancer from the GINECO/ENGOT PAOLA-1 trial.
 
Adrien Buisson
Honoraria - SOPHiA Genetics
Travel, Accommodations, Expenses - SOPHiA Genetics
 
Pierre Saintigny
Honoraria - Archer; Bristol Myer Squibb; HTG Molecular Diagnostics; Inivata; Roche Molecular Diagnostics
Research Funding - AstraZeneca; BMS Foundation; Illumina; Novartis; Omicure (Inst); Roche
Travel, Accommodations, Expenses - AstraZeneca; Bristol Myer Squibb; Illumina; Roche
 
Pantelis Constantoulakis
Speakers' Bureau - AstraZeneca
 
Katerina Oikonomaki
No Relationships to Disclose
 
Stavroula Samara
No Relationships to Disclose
 
Philipp Harter
Honoraria - AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Lilly; MSD Oncology; Roche; Sotio; Stryker; Zai Lab
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; GlaxoSmithKline; Immunogen; Merck; Roche; Tesaro
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Roche (Inst)
 
Sandro Pignata
Honoraria - AstraZeneca; GlaxoSmithKline; MSD; pfizer; pharmamar; Roche; Tesaro
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Pfizer; PharmaMar; Roche; tesaro
Research Funding - AstraZeneca (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst)
 
Antonio Gonzalez Martin
Consulting or Advisory Role - Alkermes; Amgen; AstraZeneca; Clovis Oncology; Genmab; Hedera Dx; Immunogen; Macrogenics; Mersana; MSD; Novartis; Novocure; Oncoinvent; Pfizer/EMD Serono; Roche; Seagen; SOTIO; Sutro Biopharma; Takeda; Tesaro/GSK
Speakers' Bureau - AstraZeneca; Clovis Oncology; MSD Oncology; PharmaMar; Roche; Tesaro/GSK
Research Funding - Roche (Inst); Tesaro/GSK (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD Oncology; PharmaMar; Roche; Tesaro/GSK
 
Christian Schauer
No Relationships to Disclose
 
Keiichi Fujiwara
Honoraria - Chugai Pharma; Daiichi Sankyo; Eisai; Genmab; Taiho Pharmaceutical; Takeda; Zeria Pharmaceutical
Consulting or Advisory Role - Eisai; Genmab; MSD; NanoCarrier; Seagen; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Genmab (Inst); MSD (Inst); Regeneron (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Genmab
 
Ignace Vergote
Consulting or Advisory Role - Agenus; Akeso Biopharma; AstraZeneca; Bristol Myers Squibb; Deciphera; Eisai; Elevar Therapeutics; Exelixis; Genmab; GlaxoSmithKline; Immunogen; Jazz Pharmaceuticals; Karyopharm Therapeutics; Mersana; MSD; Novartis; Novocure; Oncoinvent; OncXerna Therapeutics; Regeneron; Roche; Sanofi; Seagen; Sotio; Verastem; Zentalis
Research Funding - Amgen (Inst); Oncoinvent (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Genmab; Karyopharm Therapeutics; Novocure
 
Nicoletta Colombo
Employment - Sarepta Therapeutics (I)
Honoraria - Advaxis; Amgen; AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Novartis; Nuvation Bio; Pfizer; Pfizer; Roche/Genentech
Consulting or Advisory Role - Advaxis; AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Nuvation Bio; Pfizer; Pfizer; Roche/Genentech
 
Eric Pujade-Lauraine
Employment - Arcagy-Gineco
Honoraria - AstraZeneca; GlaxoSmithKline
Consulting or Advisory Role - AGENUS; AstraZeneca; Incyte; Merck; Roche
Research Funding - AstraZeneca (Inst)
Other Relationship - Arcagy-Gineco
 
Isabelle Treilleux
No Relationships to Disclose
 
Isabelle Laure Ray-Coquard
Honoraria - Abbvie; Advaxis; AGENUS; Amgen; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Daiichi Sankyo; DECIPHERA; Genmab; GlaxoSmithKline; Macrogenics; MERSANA; MSD Oncology; Novartis; OxOnc; Pfizer; PharmaMar; Roche; Seagen; Sutro Biopharma; Tesaro
Consulting or Advisory Role - Abbvie; AGENUS; AstraZeneca; Blueprint Medicines; BMS; Bristol-Myers Squibb; Clovis Oncology; Daichi; Deciphera; Eisai; Genmab; GlaxoSmithKline; Macrogenics; Mersana; MSD Oncology; Novartis; Novocure; Ose pharma; Pfizer; PharmaMar; Roche; Seagen; Sutro Biopharma; Tesaro
Research Funding - BMS; MSD Oncology; Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Advaxis; AstraZeneca; BMS; Clovis Oncology; Clovis Oncology; GlaxoSmithKline; PharmaMar; Roche; Tesaro
(OPTIONAL) Uncompensated Relationships - Arcagy-Gineco; Belgium health authorities; French National Cancer Institute (INCA); GERMAN health authorities; ITALIAN HEALTH AUTORITIES